Vaxxinity to Participate at the Jefferies Healthcare Conference
June 02, 2022 07:00 ET
|
Vaxxinity, Inc.
DALLAS, June 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
Vaxxinity Reports First Quarter 2022 Financial Results and Provides Corporate Updates
May 09, 2022 07:42 ET
|
Vaxxinity, Inc.
DALLAS, May 09, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for...
Vaxxinity to Participate at the Bank of America Securities 2022 Healthcare Conference
May 05, 2022 07:00 ET
|
Vaxxinity, Inc.
DALLAS, May 05, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
May 02, 2022 08:00 ET
|
Vaxxinity, Inc.
DALLAS, May 02, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a company pioneering the development of a new class of immunotherapeutic vaccines, today announced that UB-311, an...
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
April 28, 2022 08:00 ET
|
Vaxxinity, Inc.
Results from UB-312’s Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the...
CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants
April 06, 2022 16:43 ET
|
Vaxxinity, Inc.
OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the development of...
Vaxxinity Announces First Participant Dosed in Phase 3 Study of Next-Generation COVID-19 Vaccine Booster
March 28, 2022 08:00 ET
|
Vaxxinity, Inc.
Pivotal Phase 3 head-to-head study will evaluate non-inferiority of heterologous booster candidate UB-612 against authorized mRNA, adenovirus vector and inactivated virus COVID-19 vaccinesAgreement...
Vaxxinity Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Updates
March 24, 2022 16:05 ET
|
Vaxxinity, Inc.
DALLAS, March 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results...
Vaxxinity Appoints Dr. Peter Powchik to Board of Directors
March 21, 2022 07:00 ET
|
Vaxxinity, Inc.
DALLAS, March 21, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines for chronic diseases, today...
Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern
February 11, 2022 09:28 ET
|
Vaxxinity, Inc.
Investigator-sponsored studies show UB-612 induces high antibody activity against multiple variants, including Alpha, Beta, Delta, Gamma and Omicron, at levels similar to or higher than approved...